Ameriprise Financial Inc. grew its stake in PAREXEL International Corporation (NASDAQ:PRXL) by 43.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 370,138 shares of the medical research company’s stock after buying an additional 111,691 shares during the quarter. Ameriprise Financial Inc. owned 0.73% of PAREXEL International Corporation worth $32,169,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Public Employees Retirement System of Ohio increased its stake in shares of PAREXEL International Corporation by 4.5% in the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 73 shares in the last quarter. Meadow Creek Investment Management LLC increased its stake in shares of PAREXEL International Corporation by 7.1% in the 1st quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 132 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PAREXEL International Corporation by 10.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock valued at $173,000 after purchasing an additional 180 shares in the last quarter. Mogy Joel R Investment Counsel Inc. purchased a new position in shares of PAREXEL International Corporation in the 2nd quarter valued at about $204,000. Finally, Invictus RG purchased a new position in shares of PAREXEL International Corporation in the 1st quarter valued at about $158,000. 87.45% of the stock is owned by institutional investors and hedge funds.

PAREXEL International Corporation (PRXL) opened at 87.99 on Monday. The stock has a market cap of $4.50 billion, a price-to-earnings ratio of 42.71 and a beta of 0.79. The company has a 50-day moving average price of $87.74 and a 200 day moving average price of $78.14. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $88.07.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The firm had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. During the same quarter in the previous year, the business posted $0.94 EPS. On average, equities research analysts predict that PAREXEL International Corporation will post $3.95 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Ameriprise Financial Inc. Has $32.17 Million Stake in PAREXEL International Corporation (PRXL)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/25/ameriprise-financial-inc-has-32-17-million-stake-in-parexel-international-corporation-prxl.html.

PRXL has been the subject of several recent analyst reports. Mizuho lifted their price target on PAREXEL International Corporation from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, May 30th. Credit Suisse Group reiterated a “neutral” rating and issued a $83.00 price objective (up from $65.00) on shares of PAREXEL International Corporation in a report on Tuesday, June 6th. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Barclays PLC cut PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research note on Tuesday, June 20th. Finally, Jefferies Group LLC restated a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $75.92.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.